Combined amphotericin B-flucytosine therapy in Aspergillus pneumonia.
The incidence of aspergillosis is increasing while the prognosis remains dismal. Standard single-drug therapy with amphotericin B offers unacceptably low cure rates. A patient with Aspergillus pneumonia was treated with a synergistic combination of amphotericin B and flucytosine. A prompt clinical response and progressive resolution of the infection were observed. Combination therapy appeared to decrease the dose of amphotericin B needed for effective therapy. It may provide improved results with decreased toxic effects.
D000666:Amphotericin B / Q000008:administration & dosage*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D003596:Cytosine / Q000031:analogs & derivatives*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000008:administration & dosage*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy* / Q000209:etiology; D013183:Sputum / Q000382:microbiology
D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine